Dabiebandavirus and Mycoplasma pneumoniae co-infection: a case report. Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease caused by Dabiebandavirus (DBV). We report a case of DBV and Mycoplasma pneumoniae (MP) co-infection. Here we reported a 57-year-old healthy male who was admitted with the presentations of fever, cough, hemoptysis, and hypotension
specimens (serum, whole blood, throat swabs) were also tested by PCR and serology for additional zoonotic agents and respiratory pathogens, and nine patients were found to have co-infection (one with influenza virus, two with hantaviruses, six with Dabiebandavirus). Risk Assessment for Langya Henipavirus (LayV) in Ontario 4 From the patients with acute LayV infection without other identified infectious
Computer-aided designing of a novel multi‑epitope DNA vaccine against severe fever with thrombocytopenia syndrome virus. Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne viral disease caused by the SFTS virus (Dabiebandavirus), which has become a substantial risk to public health. No specific treatment is available now, that calls for an effective vaccine. Given protein (NSs). To ascertain if the predicted structure would be stable and successful in preventing infection, an immunological simulation was run on it. In conclusion, we designed a multi-epitope DNA vaccine that is expected to be effective against Dabiebandavirus, but in vivo trials are needed to verify this claim.
infections. A total of 447,848 cases infected with Bunyavirales viruses were reported, and hantaviruses, Dabiebandavirus and Crimean-Congo hemorrhagic fever virus (CCHFV) had the severest disease burden. Model-predicted maps showed that Xinjiang and southwestern Yunnan had the highest environmental suitability for CCHFV occurrence, mainly related to Hyalomma asiaticum presence, while southern China had
questionSever fever with thrombocytopenia syndrome (SFTS) was infected by sever fever with thrombocytopenia syndrome virus (SFTSV, also DabieBandavirus). The review aims to collect existing evidence on global incidence and mortality of SFTS infected by SFTSV in human and prevalence (or seroprevalence) in animals. In particular, the review will provide evidence on: i) differences on regions; ii) differences been spreading in East Asia. It was initially identified in rural areas of Hubei and Henan in central China. The SFTSV was first isolated and sequenced from human blood in 2010 and later named Dabiebandavirus by the International Committee on Viruses (ICTV) in 2019. In China, SFTS spread from 108 counties (districts) in 51 prefecture-level cities in 13 provinces in 2011 to 277 counties (districts
fatality caused by Dabiebandavirus (formerly, SFTS virus [SFTSV]). There is currently no vaccine available to prevent infection or specific antiviral drugs to treat the disease. Several clinical studies related to SFTS report the association between glucocorticoids use and prognosis, but the results were inconsistent.Participants/populationSFTS patients.Inclusion: (1) Confirmed SFTS was diagnosed